Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2213-2218

  DiPaola, R S ^a   Rafi, M M ^a   Vyas, V ^a   Toppmeyer, D ^a   Rubin, E ^a   Patel, J ^a   Goodin, S ^a   Medina, M ^a   Medina, P ^a   Zamek, R ^a   Zhang, C ^a   White, E ^a   Gupta, E ^a   Hait, W N ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; PACLITAXEL; PROTEIN BCL 2; RECOMBINANT ALPHA INTERFERON;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; LIVER MICROSOME; MALE; MONONUCLEAR CELL; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0033023218     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2213     Document Type: Article

References (26)

1. Yang J, Liu X, Bhalla K, et al: Prevention of apoptosis by bcl-2: Release of cytochrome c from mitochondria. Science 275:1129-1133, 1997
2. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 83:5214-5218, 1986
3. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992
4. Tu S, McConnell K, Marin MC, et al: Combination Adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93:147-155, 1995
5. Adam L, Crepin M, Israel L: Tumor growth inhibition, apoptosis and bcl-2 down regulation of MCF-7ras tumors by sodium phenlyacetate and tamoxifen combination. Cancer Res 15:1023-1029, 1997
6. Haldar S, Jena N, Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507-4511, 1995
7. Haldar S, Chintapalli J, Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253, 1996
8. Smith MA, Parkinson DR, Cheson BD, et al: Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992
9. Majewski S, Szmurlo A, Marczak M, et al: Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Antiangiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer 57:81-85, 1994
10. Koshiji M, Adachi Y, Sogo S, et al: Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of bcl-2 expression. Clin Exp Immunol 111:211-218, 1998
11. Jewell AP, Worman CP, Lydyard PM, et al: Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Hematol 88:268-274, 1994
12. DiPaola RS, Weiss RE, Cummings KB: Effect of 13-cis retinoic acid and alpha-interferon on transforming growth factor beta-1 in patients with rising prostate-specific antigen. Clin Cancer Res 3:1999-2004, 1997
13. Gingrich JR, Tucker JA, Walther PJ, et al: Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J Urol 146:915-919, 1991
14. Haldar S, Basu A, Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57:229-233, 1997
15. Gibaldi M: Compartmental and noncompartmental pharmacokinetics, in Biopharmaceutics and Clinical Pharmacokinetics (ed 4). Baltimore, MD, Williams & Wilkins, 1991, pp 14-23
16. Jurima M, Inaba T, Kalow W: Mephenytoin metabolism in vitro by human liver. Drug Metab Dispos 13:151-154, 1985
17. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
18. Lippman SM, Parkinson DR, Itri LM, et al: 13-cis-retinoic acid and interferon-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-240, 1992
19. Lippman SM, Kavanagh JJ, Paredes-Espinoza, et al: 13-cis-retinoic acid plus interferon-2alpha: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992
20. Motzer RJ, Schwartz L, Law T, et al: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase n trial and interactions in vitro. J Clin Oncol 13:1950-1957, 1995
21. Sonnichsen DS, Relling MV: Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27:256-269, 1994
22. Rahman A, Korzekwa KR, Grogan J, et al: Selective biotransformation of Taxol to 6alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546, 1994
23. Harris JW, Rahman A, Kim BR, et al: Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035, 1994
24. Leo MA, Lasker JM. Raucy JL, et al: Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch Biochem Biophys 269:305-312, 1989
25. Agarwal N, Mehta K: Possible involvement of bcl-2 pathway in retinoid X receptor alpha-induced apoptosis of HL-60 cells. Biochem Biophys Res Comm 230:251-253, 1997
26. Handa H, Hegde UP, Kotelnikov VM, et al: The effects of 13-cis retinoic acid and interferon alpha in chronic myelogenous leukemia cells in vivo in patients. Leuk Res 21:1087-1096, 1997